Fig. 5. Reversion of human PBMC-derived pOCs by JNK blockade. (A,B) PBMCs were cultured with M-CSF (100 ng/ml) and RANKL (100 ng/ml) for 3 days to the pOC stage. pOCs were treated with (+SP) or without (–SP) SP600125 (10 µM) for 24 hours and TRAP⁺ cells were counted. (C,D) PBMCs, PBMC-derived pOCs and pOCs treated with (+SP) or without (–SP) SP for 24 hours were incubated with FITC-zymosan and subjected to flow cytometry as described in the Materials and Methods. (C) n.c., negative control cells incubated without FITC-zymosan and stained with FITC-Ig. The x-axes represent fluorescence intensity for FITC-zymosan-positive cells. (B,D) Error bars represent s.d. from triplicate samples. Similar results were obtained in three independent experiments.